Explore Lineage Cell Therapeutics' Q1 2025 insights, including OpRegen progress, a manufacturing milestone, key clinical data, and a strong financial outlook.

"We are thrilled with the overwhelmingly positive response from the Sarasota community,” said Brandon Lacoff, CEO of Belpointe OZ. "Reaching this milestone validates the demand for a sophisticated ...